The increased risk for breast cancer that occurs after childbirth can last more than 20 years. The risk may be enhanced when a woman is older at first birth or has a family history of breast cancer, and is not mitigated by breastfeeding.
from Breast Cancer News -- ScienceDaily https://ift.tt/2Edw4wb
Monday, December 10, 2018
Increased risk for breast cancer after childbirth may last more than 20 years
The increased risk for breast cancer that occurs after childbirth can last more than 20 years. The risk may be enhanced when a woman is older at first birth or has a family history of breast cancer, and is not mitigated by breastfeeding.
from Women's Health News -- ScienceDaily https://ift.tt/2Edw4wb
from Women's Health News -- ScienceDaily https://ift.tt/2Edw4wb
Increased risk for breast cancer after childbirth may last more than 20 years
The increased risk for breast cancer that occurs after childbirth can last more than 20 years. The risk may be enhanced when a woman is older at first birth or has a family history of breast cancer, and is not mitigated by breastfeeding.
from Women's Health News -- ScienceDaily https://ift.tt/2Edw4wb
from Women's Health News -- ScienceDaily https://ift.tt/2Edw4wb
Sprayable gel could help the body fight off cancer after surgery
A research team has developed a spray gel embedded with immune-boosting drugs that could help lower the risk of cancer recurrence after surgery.
from Women's Health News -- ScienceDaily https://ift.tt/2C22qbv
from Women's Health News -- ScienceDaily https://ift.tt/2C22qbv
Sprayable gel could help the body fight off cancer after surgery
A research team has developed a spray gel embedded with immune-boosting drugs that could help lower the risk of cancer recurrence after surgery.
from Women's Health News -- ScienceDaily https://ift.tt/2C22qbv
from Women's Health News -- ScienceDaily https://ift.tt/2C22qbv
Imaging atomic structure of important immune regulator
A new study provides a biophysical and structural assessment of a critical immune regulating protein called human T-cell immunoglobulin and mucin domain containing protein-3 (hTIM-3). Understanding the atomic structure of hTIM-3 provides new insights for targeting this protein for numerous cancer and autoimmune therapeutics currently under clinical development.
from Women's Health News -- ScienceDaily https://ift.tt/2SCVlDN
from Women's Health News -- ScienceDaily https://ift.tt/2SCVlDN
Imaging atomic structure of important immune regulator
A new study provides a biophysical and structural assessment of a critical immune regulating protein called human T-cell immunoglobulin and mucin domain containing protein-3 (hTIM-3). Understanding the atomic structure of hTIM-3 provides new insights for targeting this protein for numerous cancer and autoimmune therapeutics currently under clinical development.
from Women's Health News -- ScienceDaily https://ift.tt/2SCVlDN
from Women's Health News -- ScienceDaily https://ift.tt/2SCVlDN
Sunday, December 9, 2018
Insufficient nutrition during fetal development may lead to early menopause
Previous studies have demonstrated that fetal malnutrition can lead to adult chronic disorders such as type 2 diabetes and coronary artery disease. A new study out of China now suggests that it also can lead to early menopause and premature ovarian failure.
from Women's Health News -- ScienceDaily https://ift.tt/2EozkG3
from Women's Health News -- ScienceDaily https://ift.tt/2EozkG3
Insufficient nutrition during fetal development may lead to early menopause
Previous studies have demonstrated that fetal malnutrition can lead to adult chronic disorders such as type 2 diabetes and coronary artery disease. A new study out of China now suggests that it also can lead to early menopause and premature ovarian failure.
from Women's Health News -- ScienceDaily https://ift.tt/2EozkG3
from Women's Health News -- ScienceDaily https://ift.tt/2EozkG3
Friday, December 7, 2018
Circulating tumor cell count could help choose treatment for metastatic breast cancer patients
Circulating tumor-cell (CTC) count could be used to choose hormone therapy or chemotherapy as frontline treatment for patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer, according to data from the phase III STIC CTC clinical trial. In the case of discrepancy between CTC count-based treatment choice and physician's choice of treatment, frontline chemotherapy was associated with a significant gain in overall survival.
from Breast Cancer News -- ScienceDaily https://ift.tt/2zQdbwd
from Breast Cancer News -- ScienceDaily https://ift.tt/2zQdbwd
Subscribe to:
Posts (Atom)